Deep dive #10 · 13 November 2026

Pelvic congestion syndrome

For health professionals Women's health Vascular and interventional radiology

Pelvic congestion syndrome is varicose veins where nobody looks: a dragging pelvic ache that builds by evening, a pelvic scan "within normal limits", and years between clinics. Its own experts now want the name retired in favour of "pelvic venous disorders". The hard part isn't seeing the veins. It's proving they cause the pain, because plenty of pain-free women have them too. Here's what the evidence can and can't say.

At a glance

What it is: chronic pelvic pain of venous origin from ovarian or internal iliac vein reflux, sometimes with outflow compression (left renal vein, iliac vein). New name: pelvic venous disorders, classified by SVP (2021).
The story: dull ache worse on standing and later in the day, deep dyspareunia, post-coital ache; vulval, buttock or thigh varices. Ovarian point tenderness plus post-coital ache: 94% sensitive, 77% specific (Beard 1988, n=57).
The catch: ovarian vein reflux in 44% of pain-free parous women (Hiromura 2004). But in a case-control study, reflux was 62% vs 19% and varices 27% vs 2% (Hansrani 2023).
Test: transvaginal duplex of the pelvic veins, asked for specifically; CT or MR venography for planning; catheter venography is the reference.
Treatment: embolisation helps about 75% early in case series (1,308 women), and the first blinded RCT (n=60) favoured coils over venography alone at 12 months. Hormonal suppression helps while taken.

Biggest take-home: think of it in women with positional pelvic pain and vulval or atypical leg varices, but treat the imaging as a clue, not a verdict. The vein has to fit the story.

For patients: Pelvic congestion syndrome, Endometriosis and Varicose veins.

Definition

Pelvic congestion syndrome (PCS): chronic pelvic pain (usually 6 months or more) attributed to reflux or obstruction in the pelvic veins, with dilated pelvic varices.
Pelvic venous disorders (PeVD): the umbrella term. The SVP classification (Meissner 2021, AVLS-convened international panel) recommends dropping "pelvic congestion", "nutcracker" and "May–Thurner syndrome".
SVP domains: Symptoms (S0–S3: S1 renal, S2 chronic pelvic pain, S3 genital, leg or claudication symptoms), Varices (V0–V3) and Pathophysiology (anatomy, haemodynamics: obstruction or reflux, aetiology: thrombotic, non-thrombotic or congenital).
Four zones: 1 left renal vein; 2 gonadal and internal iliac veins and pelvic plexuses; 3 pelvic-origin veins outside the pelvis via "escape points"; 4 leg veins (classified with CEAP).
Pelvic varices: tortuous, dilated veins ≥5 mm around the ovary and uterus (SVP).
SIR 2026 term: "venous-origin chronic pelvic pain".

History

1857, Richet: first description of pelvic varicose veins.
1949, Howard C. Taylor: "vascular congestion and hyperemia" and the congestion-fibrosis syndrome, a psychosomatic-vascular theory of pelvic pain.
1957, Ralph May and Josef Thurner: a "spur" where the right common iliac artery crosses the left common iliac vein, in 22% of 430 cadavers.
1958, R. Topolanski-Sierra: pelvic phlebography, making the veins visible.
1972, A. de Schepper: named the renal vein "nutcracker" phenomenon, in Dutch, in a Belgian radiology journal.
1984, Richard Beard and colleagues: transuterine venography in 45 women with chronic pelvic pain and a normal laparoscopy (Lancet).
1989, Cindy Farquhar: the first RCT of medical treatment (medroxyprogesterone ± psychotherapy, n=84).
1993, R.D. Edwards (Glasgow): first reported ovarian vein embolisation for pelvic pain, a single case. In 2003 Chung and colleagues in Korea compared embolisation with hysterectomy in 106 women.

Pathophysiology

Reflux down incompetent ovarian and internal iliac veins, sometimes pushed by outflow compression, dilates the pelvic plexus. Why only some women hurt is the open question.

Valves: often absent or incompetent. Valves are absent in about 15% of ovarian veins and incompetent in about 40% on the left and 35% on the right where present (Asciutto 2012, citing earlier venographic and cadaver work). Only about 10% of internal iliac veins have valves (Black 2015).
Asymmetry: the left ovarian vein drains at a right angle into the left renal vein; the right drains into the IVC (into the right renal vein in about 10%).
Pregnancy and oestrogen: parity is the strongest association (reflux in 63% of parous vs 10% of nulliparous kidney donors; Rozenblit 2001). Oestradiol dilates veins; GnRH suppression improved venograms more than MPA (Soysal 2001).
Compression is common anatomy: ≥50% left renal vein compression on 51–72% of CT angiograms (Meissner 2021); >50% left common iliac vein compression in 24% of 50 ED CTs, mean 41.2% in women vs 27.0% in men (Kibbe 2004).
Pain mechanism (hypothesis): wall stretch and stasis activating nociceptors, possibly with substance P; perineural venous congestion of sacral roots has also been proposed (Berthelot 2021).
Escape points: reflux can leave the pelvis through pelvic "escape points" to feed vulval, buttock and leg varices (zone 3; Meissner 2021).

Pelvic venous disorder: from reflux and compression to varices and pain, with the big caveat (simplified; Meissner 2021, Hiromura 2004, Hansrani 2023). Download this diagram

Epidemiology

Chronic pelvic pain is common: non-cyclical pelvic pain 2.1–24% of women in high-quality studies (WHO systematic review, 178 studies, n=459,975; Latthe 2006); data from only 1 of 45 least-developed countries.
Share due to venous disease: often quoted as 16–31% or "30–40%", but these come from venography series, not population studies. Treat as soft.
Best case-control data: pelvic vein reflux (>0.7 s) in 62% of 164 women with chronic pelvic pain vs 19% of 164 matched pain-free controls (OR 6.79); varices 27% vs 2% (OR 18.9; Hansrani 2023).
Who: usually women aged 20–45, mostly parous (mean age 32.4 in Beard's 1988 cohort).
Leg veins: 15.8% of 462 women with varicose veins had confirmed pelvic truncal reflux (Marsh 2009); about 17% of 170 recurrent varices had pelvic reflux (Perrin, cited in Black 2015).
Men: rare in practice (under 0.1% of venous patients); in SVP the male varicocele is V3a.

Causes and risk factors

Parity: ovarian vein reflux in 44% of 110 asymptomatic parous women vs 5% of 41 nulliparous (Hiromura 2004).
Primary reflux: absent or incompetent gonadal and internal iliac valves.
Outflow obstruction: left renal vein compression (zone 1) and non-thrombotic iliac vein lesions; in one stenting centre's series, 80% of 227 women had >50% iliac stenosis on IVUS (Santoshi 2018; selection bias likely).
Post-thrombotic disease: the "T" aetiology in SVP.
Polycystic ovarian morphology: 40.6% vs 11.4% of controls on ultrasound (Park 2004); association, not cause.
Shared venous biology: leg varicose veins have about 17% heritability and 46 loci in extracellular matrix pathways (GWAS, n=810,625); pelvic-specific genetics are unstudied.

Preventable factors

No proven primary prevention. The main risk factors (pregnancy, venous anatomy) aren't sensible targets.
Prevent the diagnostic odyssey: ask about positional pain, post-coital ache and vulval varices in chronic pelvic pain, and check atypical or recurrent leg varices for a pelvic source.
Prevent recurrence after leg vein surgery: pelvic reflux feeds recurrences; 13% of 179 women had leg recurrence 5 years after pelvic coiling (Hansrani 2015 review), but the trial testing routine pre-treatment (NCT01909024, n=270) has no published results.
Prevent harm: rule out endometriosis, adenomyosis and other causes before attributing pain to veins, and screen for depression, anxiety and catastrophising (SIR 2026).

Diagnosis essentials

History: dull ache with sharp exacerbations, can switch sides, worse with posture changes, walking and standing; congestive dysmenorrhoea, deep dyspareunia, post-coital ache (Beard 1988).
Examination: ovarian point tenderness (junction of the upper and middle thirds of a line from umbilicus to ASIS); vulval, perineal, buttock or posterior thigh varices.
Transvaginal duplex (first line): left ovarian vein 7.9 vs 4.9 mm, reversed flow in 22/22 patients vs 4/16 controls, dilated arcuate veins crossing the myometrium (Park 2004). No validated reflux-time cut-off (some use >1 s). Request it specifically and do it standing or with Valsalva where possible.
Diameter is a weak test: positive predictive value 71% at 5 mm, 83% at 6 mm, 76% at 8 mm (Meissner 2021). Transuterine crossing veins: 25% of patients vs 8.6% of controls.
CT or MR venography: for anatomy, compression and planning; done supine, so they underestimate reflux.
Catheter venography (reference): ovarian vein >10 mm, uterine engorgement, ovarian plexus engorgement, filling across the midline or of vulvo-thigh varices. Beard's 1984 venogram score ≥5: sensitivity 91%, specificity 89%.
Before embolising: check whether left renal vein compression is haemodynamically significant (SIR 2026). Laparoscopy can miss varices because pneumoperitoneum and head-down tilt collapse them.
Overlap: endometriosis in 19% of a Zurich series (n=43) but 4.4% of a 2,544-woman US registry; adenomyosis in 8 of 36 hysterectomy specimens (Beard 1991). Look for both.

Current treatment

Medical

Medroxyprogesterone: ≥50% pain improvement in 73% vs 33% on placebo during 4 months of treatment; no overall difference 9 months after stopping, except MPA plus psychotherapy (71% still improved) (Farquhar 1989, n=84).
Goserelin vs MPA: goserelin 3.6 mg monthly for 6 months beat MPA 30 mg daily at 1 year on venogram score, pain, sexual function and mood (Soysal 2001, n=47). Limit: bone loss with prolonged GnRH use; RCOG grades the progestogen and GnRH evidence D.
Etonogestrel implant: VAS 7.7 to 4.6 at 6 months; venogram score 4.2 vs 8.5 at 1 year (pilot RCT, n=23).
Micronised purified flavonoid fraction: lower symptom scores at 6 months vs placebo (crossover RCT, n=20).

Embolisation

Systematic reviews: about 75% early substantial relief, sustained or improving (1,308 women, low-quality evidence; Daniels 2016, Champaneria 2016). Technical success 99.8% in 866 women; coil migration 1.6%, vein perforation 0.6%, no deaths (Hansrani 2015).
First blinded RCT: coil embolisation vs venography alone, n=60, stopped early by COVID. At 12 months SF-MPQ pain index median 3 vs 9 (p=0.016), VAS 15 vs 53 (p=0.002), better EQ-5D; 15% lost to follow-up (Hansrani 2023).
Cohorts: VAS 7.6 to 2.9 at a mean 45 months; 83% improved, 13% unchanged, 4% worse (Kim 2006, n=127). Clinical success 94%, complete resolution 33.5% at 5 years (Laborda 2013, n=202).
Side effects: post-embolisation syndrome in 20% (Gavrilov 2020); coils have reached the lungs (2 of 218; Ratnam 2008). Hormone levels didn't change (Kim 2006).
Australia: no specific MBS item yet; a September 2025 draft MBS review proposed one for endovascular treatment of pelvic venous congestion or varicocele.

Surgery and stenting

Hysterectomy with bilateral oophorectomy plus HRT: median VAS 10 to 0 at 1 year (Beard 1991, n=36). Major, irreversible; now rarely first line.
Embolisation vs hysterectomy: more pain reduction with embolisation (p<0.05) in 106 women (Chung 2003; allocation method unclear).
Iliac vein stenting: in a staged series, VAS 8.6 before, 7.97 after embolisation alone, 1.33 after stenting (Santoshi 2018; retrospective, single stenting centre). ANZ vascular surgeons (2024) say consider stenting for pelvic pain, deep dyspareunia or post-coital pain once other causes are excluded (level Ic).
Nutcracker: left renal vein stenting improved 72% (n=18); a 2024 Delphi prefers open transposition because of stent migration risk.

Emerging treatments and trials

EMBOLIZE (NCT06168058): sham-controlled, participant-blinded embolisation trial, n=40, recruiting since October 2025; VAS at 30, 90 and 180 days; primary completion estimated June 2027.
Cyanoacrylate glue vs flavonoids: pelvic VAS 8.15 to 3.20 vs 8.35 to 5.10 at 12 months; recurrence 10% vs 45% (HR 0.12); open-label, n=40, power 55% (Eleissawy 2026).
Foam sclerosant: used by 69% of 194 specialists surveyed for pelvic embolisation; "top-down" vs "bottom-up" approach still in equipoise (JVS-VL 2026).
Pelvic coiling before leg vein surgery: RCT NCT01909024 (n=270), status unknown, no results posted.
Classification in trials: SIR 2026 recommends SVP and validated pain and mood scores, so trials can finally be compared.

Theoretical frontiers

Hypotheses, not recommendations.

Causes: theories

Hypothesis: varices are often bystanders. For: reflux in 44–47% of pain-free parous women (Hiromura 2004; Rozenblit 2001). Against: 62% vs 19% reflux and 27% vs 2% varices, cases vs controls (Hansrani 2023). Test: population cohorts with standardised duplex and pain follow-up.
Hypothesis: outflow obstruction is the hidden driver. For: 80% iliac stenosis on IVUS and pain falling mainly after stenting (Santoshi 2018). Against: >50% iliac compression in 24% of the general population (Kibbe 2004); single stenting centre. Test: randomised stenting vs sham in IVUS-defined lesions.
Hypothesis: oestrogen drives the veins and the pain. For: GnRH suppression beat MPA on venograms and symptoms (Soysal 2001); parity association. Against: no direct mechanistic studies; hormone levels unchanged after embolisation (Kim 2006). Test: venous wall oestrogen-receptor studies with hormone-challenge imaging.
Hypothesis: central sensitisation decides who hurts. For: lower stress scores predicted better relief (Chung 2003); MPA plus psychotherapy lasted longest (Farquhar 1989). Against: no PCS-specific quantitative sensory testing data. Test: QST before and after embolisation.
Hypothesis: congested veins compress nerves. For: proposed perineural venous congestion of sacral roots and vasa nervorum (Berthelot 2021). Against: a narrative hypothesis without controlled data. Test: MR neurography with venous mapping and nerve-block responses.
Hypothesis: a weak vein wall is inherited. For: leg varicose vein heritability about 17%, extracellular matrix loci (GWAS, n=810,625); taller height causal (OR 1.26). Against: no pelvic-specific genetics. Test: GWAS in venography-confirmed PeVD.

Prevention: theoretical options

Hypothesis: early postpartum screening of symptomatic women shortens diagnosis. For: the parity link (63% vs 10%; Rozenblit 2001). Against: high background prevalence means false positives. Test: diagnostic accuracy study in postpartum pelvic pain clinics.
Hypothesis: treating pelvic reflux prevents leg varicose vein recurrence. For: pelvic reflux in about 17% of recurrences (Perrin). Against: 13% still recurred after coiling. Test: publish and replicate NCT01909024.
Hypothesis: venoactive drugs slow progression. For: symptom benefit vs placebo (n=20) and vs embolisation in a small trial (Eleissawy 2026). Against: no progression data. Test: long-term RCT with imaging end points.
Hypothesis: routine SVP coding prevents misattribution. For: SIR 2026 and SVP authors call for it. Against: no outcome data yet. Test: registry comparing coded vs uncoded practice.

Treatment: theoretical options

Hypothesis: much of embolisation's benefit is placebo. For: open case series, 33.5% complete resolution (Laborda 2013). Against: blinded RCT VAS 15 vs 53 (Hansrani 2023). Test: EMBOLIZE and larger sham-controlled trials.
Hypothesis: selecting by haemodynamics beats selecting by diameter. For: diameter PPV only 71–83% (Meissner 2021). Test: trials stratified by reflux and pressure gradients.
Hypothesis: glue outperforms coils and foam. For: recurrence 10% vs 45% vs flavonoids (Eleissawy 2026). Against: no head-to-head with coils; open-label. Test: randomised agent comparison.
Hypothesis: combined venous plus pain-psychology care beats either. For: MPA plus psychotherapy held benefit at 9 months (Farquhar 1989). Test: factorial RCT of embolisation with or without pain psychology.
Hypothesis: stenting first helps women with obstruction. For: Santoshi 2018 staged data. Against: retrospective. Test: randomised embolise-first vs stent-first.

Gaps and open questions

Causation: "It cannot be categorically stated that PVI is the cause of CPP" (Champaneria 2016, NIHR HTA).
No validated diagnostic criteria: no agreed diameter or reflux-time cut-offs.
One small blinded RCT of embolisation, stopped early; sham trial results expected after 2027.
Natural history: improvement after menopause is widely stated but lacks good primary data.
Pregnancy after coiling: reflux recurred in 5 of 8 women (tiny series).
Equity: almost no data from low-income settings; access to embolisation in Australia depends on private interventional services.

Prognosis and quality of life

Burden: EQ-5D 0.80 vs 1.0 in healthy controls; 88% had seen a consultant in the past year vs 30–35% of controls (Hansrani 2015 pilot).
Mood: 60% had significant emotional disturbance in Beard's 1988 series.
After embolisation: most improve; about 4% are worse (Kim 2006); leg varices recurred in 12.5% at 5 years (Laborda 2013).
Benign: pelvic varices themselves rarely cause serious harm; the burden is pain, sex and work.

Weird trivia

Migraine drug, smaller veins: IV dihydroergotamine shrank pelvic veins by 35% on venography and eased pain vs saline (Reginald 1987, Lancet).
Lost in citation: Beard's 94%/77% combo is ovarian point tenderness plus post-coital ache; several reviews misquote it as dyspareunia.
Airport-safe: platinum embolisation coils don't set off airport scanners (Black 2015).
Dose: pelvic embolisation delivers about 6 mSv, roughly 3 years of background radiation (Black 2015).
Name your own disease out: the SVP authors recommend retiring "pelvic congestion syndrome", yet the term still dominates papers, including their own.
Men too: in 8 men with leg varices, 23 of 32 pelvic truncal veins refluxed, and all were embolised.

Guidelines

Key trials

Farquhar 1989: MPA ± psychotherapy, n=84.
Soysal 2001: goserelin vs MPA, n=47.
Chung 2003: embolisation vs hysterectomy, n=106.
Hansrani 2023 (BJOG): first patient-blinded RCT of coil embolisation, n=60.
Hansrani 2023 case-control: 164 vs 164, reflux 62% vs 19%.
Eleissawy 2026: cyanoacrylate vs flavonoids, n=40.
EMBOLIZE (ongoing): sham-controlled, n=40.

Sources

Information only. Check product information, PBS criteria and current Australian guidelines before prescribing. Several hormonal and venoactive uses above are off-label in Australia.

Updated 13 November 2026. General education for health professionals; not a substitute for local protocols.

maladywise.com/deep-dives/pelvic-congestion-syndrome/